Literature DB >> 15711004

Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?

R C Fitzgerald1.   

Abstract

Acid, a principal component of gastro-oesophageal refluxate, may contribute to the development and malignant progression of Barrett's oesophagus. Oesophageal pH monitoring studies have demonstrated that patients with Barrett's oesophagus have severe and chronic acid reflux. However, there is overlap between the amount of acid exposure in patients with oesophagitis compared with patients with Barrett's oesophagus. This suggests that factors other than acid may be important in the aberrant oesophageal cell differentiation process that leads to the development of the metaplastic Barrett's mucosa. The other factors important in the aetiology of Barrett's oesophagus are poorly understood but probably include both genetic and environmental factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711004      PMCID: PMC1867792          DOI: 10.1136/gut.2004.041558

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  52 in total

1.  A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis.

Authors:  C P Caygill; P I Reed; B J Johnston; M J Hill; M H Ali; S Levi
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-12       Impact factor: 2.566

2.  Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus.

Authors:  M Umansky; W Yasui; A Hallak; S Brill; I Shapira; Z Halpern; H Hibshoosh; J Rattan; S Meltzer; E Tahara; N Arber
Journal:  Oncogene       Date:  2001-11-29       Impact factor: 9.867

3.  Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.

Authors:  D C Farrow; T L Vaughan; P D Hansten; J L Stanford; H A Risch; M D Gammon; W H Chow; R Dubrow; H Ahsan; S T Mayne; J B Schoenberg; A B West; H Rotterdam; J F Fraumeni; W J Blot
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-02       Impact factor: 4.254

Review 4.  Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression.

Authors:  R C Fitzgerald; R Lascar; G Triadafilopoulos
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

5.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery.

Authors:  W Ye; W H Chow; J Lagergren; L Yin; O Nyrén
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

6.  Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.

Authors:  R F Souza; K Shewmake; D G Beer; B Cryer; S J Spechler
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

7.  Barrett's metaplasia.

Authors:  J A Jankowski; R F Harrison; I Perry; F Balkwill; C Tselepis
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

8.  Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.

Authors:  J J Going; W N Keith; L Neilson; K Stoeber; R C Stuart; G H Williams
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

9.  Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus.

Authors:  Rhonda F Souza; Kenneth Shewmake; Lance S Terada; Stuart Jon Spechler
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

10.  Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal.

Authors:  J Fletcher; A Wirz; J Young; R Vallance; K E McColl
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

View more
  19 in total

1.  Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.

Authors:  Christopher John Lewis; Sri Ganeshamurthy Thrumurthy; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2011-02-27       Impact factor: 4.584

2.  Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.

Authors:  I Tischoff; U R Hengge; M Vieth; C Ell; M Stolte; A Weber; W E Schmidt; A Tannapfel
Journal:  Gut       Date:  2007-03-21       Impact factor: 23.059

3.  Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries.

Authors:  John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

4.  Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase Cgamma2 and NADPH oxidase NOX5-S.

Authors:  Jie Hong; Jose Behar; Jack Wands; Murray Resnick; Li Juan Wang; Ronald A Delellis; David Lambeth; Weibiao Cao
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

5.  Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma.

Authors:  Jie Hong; Jose Behar; Jack Wands; Murray Resnick; Li Juan Wang; Ronald A DeLellis; David Lambeth; Rhonda F Souza; Stuart J Spechler; Weibiao Cao
Journal:  Gut       Date:  2009-11-18       Impact factor: 23.059

Review 6.  Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children.

Authors:  Eric Hassall
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 7.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.

Authors:  Rajesh Krishnamoorthi; Bijan Borah; Herbert Heien; Ananya Das; Amitabh Chak; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2016-01-07       Impact factor: 9.427

9.  Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma.

Authors:  Jón O Kristinsson; Paul van Westerveld; Rene H M te Morsche; Hennie M J Roelofs; T Wobbes; Ben J M Witteman; Adriaan C I T L Tan; Martijn G H van Oijen; Jan B M J Jansen; Wilbert H M Peters
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

Review 10.  Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Sushil Kumar Garg; Preet Paul Singh; Prasad G Iyer; Hashem B El-Serag
Journal:  Gut       Date:  2013-11-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.